Market Cap | 68.23M | P/E | - | EPS this Y | 41.90% | Ern Qtrly Grth | - |
Income | -26.54M | Forward P/E | -3.39 | EPS next Y | 15.30% | 50D Avg Chg | 41.00% |
Sales | 10.76M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 173.00% |
Dividend | N/A | Price/Book | 4.34 | EPS next 5Y | - | 52W High Chg | -39.00% |
Recommedations | 2.50 | Quick Ratio | 1.87 | Shares Outstanding | 32.96M | 52W Low Chg | 705.00% |
Insider Own | 8.93% | ROA | -30.31% | Shares Float | 16.51M | Beta | - |
Inst Own | 48.71% | ROE | -97.40% | Shares Shorted/Prior | 274.42K/51.61K | Price | 2.07 |
Gross Margin | -185.15% | Profit Margin | -246.71% | Avg. Volume | 529,309 | Target Price | 2.50 |
Oper. Margin | -240.64% | Earnings Date | Nov 14 | Volume | 152,923 | Change | 0.00% |
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..
Chardan Capital | Buy | Aug 22, 22 |
Chardan Capital | Buy | May 17, 22 |
JMP Securities | Market Outperform | May 10, 22 |
William Blair | Market Perform | Feb 3, 22 |
Chardan Capital | Hold | Feb 2, 22 |
Chardan Capital | Buy | Dec 23, 21 |
Barclays | Overweight | Nov 17, 21 |
JMP Securities | Market Outperform | Nov 16, 21 |
HC Wainwright & Co. | Buy | Jun 7, 21 |